Avandra Health acquires DatCard and Sorna to build industry-leading medical imaging platform
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Subscribe To Our Newsletter & Stay Updated